Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Insight Molecular Diagnostics Inc.

NASDAQ: IMDX · Life Sciences · 3 alerts · CIK 1642380

Share price
$1.86Close, Nov 16
Market cap
$60.9M
Shares outstanding
32.76MLatest SEC cover page
Sector
Life Sciences
Industry
In Vitro & In Vivo Diagnostic SubstancesSIC 2835

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Insight Molecular Diagnostics Inc. filings on SEC EDGAR ↗

4:10 PM ET 10-Q
Financial Results

Insight Molecular Diagnostics Q3 2026 Results: Net Loss of $3.58M, Loss Narrows

Insight Molecular Diagnostics Inc. (iMDx) reported a net loss of $19.1 million for the nine months ended September 30, 2026, an improvement from a $27.3 million loss in the prior year period. The company's financial position remains under pressure with a total shareholders' deficit of $24.2 million and a significant contingent consideration liability of $35.3 million.

Key figure
Net loss $3.58M
4:09 PM ET 8-K
Financial Results

Insight Molecular Diagnostics Financial Results

Insight Molecular Diagnostics reported Q3 2026 financial results, highlighting revenue of $559,000 and progress on its FDA de novo submission for GraftAssureDx. The company also announced the initiation of patient enrollment in its GALACTIC registry study at UCLA Medical Center to support its decentralized testing thesis.

Term
Q3 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.